<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742375</url>
  </required_header>
  <id_info>
    <org_study_id>S60050</org_study_id>
    <nct_id>NCT03742375</nct_id>
  </id_info>
  <brief_title>Quantitative HPV Genotyping in Screening of Anal Intraepithelial Neoplasia in HIV-positive Patients</brief_title>
  <acronym>GAIN</acronym>
  <official_title>Quantitative HPV Genotyping in Screening of Anal Intraepithelial Neoplasia in HIV-positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sciensano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pathophysiology from anal HPV infection to Anal Intraepithelial Neoplasia is less well
      understood than cervical HPV infection. In cervical screening programs it is well accepted
      that the sole presence of a high-risk HPV strain (irrespective of number of viral particles)
      is sufficient to justify further investigation and treatment. The investigators hypothesize
      that in anal HPV infection not only the presence but the extent of HPV infection (single
      genotype viral load) or combination of different HPV genotypes (cumulative viral load) is of
      importance in determining the risk of anal dysplasia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HPV subtypes in HIV-positive patients</measure>
    <time_frame>1 minute</time_frame>
    <description>Retrieval of 1 anal swab before performing HRA to determine the HPV subtypes at that particular moment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between high-resolution anoscopy findings and quantitative HPV genotyping</measure>
    <time_frame>30 minutes up to 10 days</time_frame>
    <description>Performing HRA (30 minutes) with or without biopsies, results biopsies up to 10 days</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>HPV genotyping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>HPV genotyping</intervention_name>
    <description>Quantitative HPV genotyping on anal swab</description>
    <arm_group_label>HPV genotyping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Stable HIV disease (i.e. receiving ART for at least 1 year, no adverse drug reactions
             requiring regular monitoring, no current illnesses or pregnancy, good understanding of
             lifelong adherence and evidence of treatment success: two consecutive undetectable
             viral load measures)

          -  Referred for high-resolution anoscopy

        Exclusion criteria

          -  Documented AIN (treated or untreated)

          -  Local anal inflammation (proctitis) and/or acute fissure
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Roelandt, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip Roelandt, MD PhD</last_name>
    <phone>+32 16 34 42 25</phone>
    <email>philip.roelandt@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Roelandt, MD PhD</last_name>
      <phone>+32 16 34 42 25</phone>
      <email>philip.roelandt@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Jan Wyndaele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>November 14, 2018</last_update_submitted>
  <last_update_submitted_qc>November 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>prof. dr. Philip Roelandt</investigator_full_name>
    <investigator_title>Assistant head of clinic Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Human Papilloma Virus</keyword>
  <keyword>Anal Intraepithelial Neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

